Randomized 68% Recurrence Cut Faces Durability and No-Treatment Comparator Scrutiny
Clinical Trial Updates

Randomized 68% Recurrence Cut Faces Durability and No-Treatment Comparator Scrutiny

Published : 17 Nov 2026

The Overview
CG Oncology announced positive Phase III results for its gene therapy, cretostimogene grenadenorepvec, in the PIVOT-006 trial for intermediate-risk and high-grade Ta ≤3 cm non-muscle invasive bladder cancer (NMIBC). The adenovirus-based oncolytic viral immunotherapy demonstrated a 68% reduction in the risk of recurrence (HR 0.32) compared to no intervention, with a median follow-up of 17 months. This success, which saw CG Oncology's stock rise by 23.7%, supports a broadened Biologics License Application (BLA) submission to the FDA in Q2 2027, expanding its potential use beyond BCG-unresponsive NMIBC. The therapy was well tolerated, with no Grade 3 or greater treatment-related adverse events.
Knolens Analysis

CG Oncology delivered the only randomized Phase 3 signal among oncolytic virus datasets in bladder cancer, with cretostimogene grenadenorepvec cutting recurrence risk by 68% with HR 0.32 versus no intervention at 17 months median follow-up in intermediate-risk and high-grade Ta ≤3 cm NMIBC, with no Grade 3 or greater treatment-related events. The result underpins a broadened BLA submission in Q2 2027 beyond BCG-unresponsive disease, where single-arm Phase 3 BOND-003 Cohort C reported 75% complete response in 83 of 110 patients and Phase 2 CORE-001 with pembrolizumab reported 57.1% complete response at 12 months. [1] No closely comparable precedent exists that shares both the serotype-5 oncolytic adenovirus with Rb-E2F selectivity and GM-CSF encoding and the intermediate-risk randomized versus observation context, so regulatory analogy to nadofaragene firadenovec, pembrolizumab and nogapendekin alfa inbakicept plus BCG in BCG-unresponsive CIS cannot carry weight. Payer positioning benefits from bladder-limited toxicity and intravesical cystectomy avoidance ≥89% at 12 months versus systemic pembrolizumab with 14% grade ≥3 events, but absolute recurrence rates by arm, duration of response, progression to muscle-invasive disease and cystectomy avoidance for PIVOT-006 remain undisclosed. [2] The no-intervention comparator will require justification against gemcitabine-docetaxel with 71% 2-year recurrence-free survival and mitomycin reducing recurrence by 30-50% in retrospective series. [3][4]

PIVOT-006 Phase 3 RCT HR 0.32 at 17 months with no Grade ≥3 events, but no absolute rates, duration, progression or cystectomy data and no mechanistically matched precedent.

At a Glance
IndicationNon-muscle invasive bladder cancer (NMIBC)
Drugcretostimogene grenadenorepvec
Mechanism of Actiononcolytic viral immunotherapy
CompanyCG Oncology
Trial PhasePhase III
Trial AcronymPIVOT-006
NCT IDNCT06111235
CategoryClinical Trial Event
Sub CategoryTopline Results Positive
Therapeutic AreaOncology
Patient Populationintermediate-risk and high-grade Ta ≤3 cm NMIBC, following complete tumour resection (TURBT)
Hazard Ratio0.32
Risk Reduction68%
Median Follow-up17 months
Trial Enrollment367 patients
Regulatory AgencyUS Food and Drug Administration (FDA)
Regulatory DesignationsFast Track, Breakthrough Therapy
BLA Submission TimelineSecond quarter of 2027
Stock Price Increase23.7%
Bladder Cancer Market Projection (2033)$16bn

CG Oncology's Gene Therapy Achieves Second Pivotal Win in NMIBC

CG Oncology announced positive Phase III results for its gene therapy, cretostimogene grenadenorepvec, in the PIVOT-006 trial for intermediate-risk and high-grade Ta ≤3 cm non-muscle invasive bladder cancer (NMIBC). The adenovirus-based oncolytic viral immunotherapy demonstrated a 68% reduction in the risk of recurrence (HR 0.32) compared to no intervention, with a median follow-up of 17 months. This success, which saw CG Oncology's stock rise by 23.7%, supports a broadened Biologics License Application (BLA) submission to the FDA in Q2 2027, expanding its potential use beyond BCG-unresponsive NMIBC. The therapy was well tolerated, with no Grade 3 or greater treatment-related adverse events.

  • Significant Efficacy in NMIBC: Cretostimogene grenadenorepvec achieved a 68% reduction in the risk of recurrence (Hazard Ratio: 0.32) in patients with intermediate-risk and high-grade Ta ≤3 cm NMIBC following complete tumor resection in the pivotal Phase III PIVOT-006 trial. This outcome, observed over a median follow-up of 17 months, positions the gene therapy as the first to demonstrate such a substantial benefit in this specific patient population, marking a critical advancement in NMIBC treatment.
  • Favorable Safety and Tolerability Profile: The investigational oncolytic immunotherapy exhibited a generally well-tolerated safety profile, consistent with findings from previous studies. The PIVOT-006 trial reported no Grade 3 or greater treatment-related adverse events (TRAEs) and no treatment-related discontinuations. This robust safety data, coupled with the significant efficacy, supports the therapy's potential for broad clinical application in NMIBC patients.
  • Expanded Regulatory Pathway and Market Impact: Building on these positive results, CG Oncology plans to submit a broadened Biologics License Application (BLA) to the FDA in the second quarter of 2027. This expanded application will seek approval for intermediate-risk and high-grade Ta NMIBC, in addition to the previously targeted BCG-unresponsive NMIBC. The news led to a 23.7% surge in CG Oncology's stock, reflecting strong investor confidence and highlighting the therapy's potential to capture a significant share of the growing bladder cancer market, projected to reach $16 billion by 2033.

PIVOT-006: Cretostimogene's Efficacy and Safety in NMIBC

Recent studies in BCG-unresponsive non-muscle-invasive bladder cancer focus on bladder-preserving alternatives to radical cystectomy, including IL-15 agonist combinations, systemic PD-1 inhibition, and gene therapy. The studies below report complete response rates, durability, survival, and treatment-related toxicity in this population.

  • QUILT-3.032 — nogapendekin alfa inbakicept (NAI) in combination with BCG: Participants received 400 mcg NAI in combination with 50 mg BCG through intravesical instillation weekly for 6 weeks, with optional reinduction if complete response (CR) was not achieved at month 3. The CR rate (n = 100) was 71% (95% CI, 61.1-79.6) with a median DOR of 26.6 months (range, 0.03-53.62). The cystectomy-free rate in the 71 responders at 24 and 36 months was 90.3% (95% CI 79.7-95.6) and 84.2% (95% CI 69.6-92.1), respectively, and DSS was 100% (95% CI 100.0-100.0) at 12 months and 98.2% (95% CI 88.2-99.8) at 36 months. Treatment-related adverse events were largely grade 1 to 2 (61%), with 3% grade 3 and no grade 4 or 5 treatment-related adverse event observed.

  • KEYNOTE-057 cohort A — pembrolizumab 200 mg intravenously every 3 weeks for up to 24 months: In adults with histologically confirmed BCG-unresponsive carcinoma in situ of the bladder, with or without papillary tumours, 39 (41%; 95% CI 30·7-51·1) of 96 patients had a complete response at 3 months with median follow-up of 36·4 months (IQR 32·0-40·7). Grade 3 or 4 treatment-related adverse events occurred in 13 (13%) patients, with the most common being arthralgia (in two [2%] patients) and hyponatraemia (in three [3%] patients), and serious treatment-related adverse events occurred in eight (8%) patients with no deaths considered treatment related.

  • Multicenter real-world experience — nadofaragene firadenovec: Forty-six patients were treated at Mayo Clinic from November 2023 through December 2024. Of 24 evaluable patients with carcinoma in situ with/without papillary disease, 79% had a CR at 3 months, with median response duration not reached and 68% (13/19) of responders still having CRs with median follow-up of 9.3 months. With median follow-up of 13.9 months, cystectomy-free and overall survival were 93% and 95%, respectively, and progression occurred in 5 patients. The most common adverse events were grade 1-2 bladder spasms (61%) and failure to fully retain the instillation (33%), with four patients having grade 3 events and no grade 4 or 5 events.

Expanding Cretostimogene's Reach Beyond Intermediate-Risk NMIBC

Beyond non-muscle-invasive disease, cretostimogene grenadenorepvec is being evaluated in cisplatin-ineligible patients with cT2-4aN0-1M0 muscle-invasive bladder cancer. This phase 1b study combines intravesical oncolytic immunotherapy with systemic checkpoint blockade to assess safety and antitumor efficacy in the neoadjuvant setting.

Indication Population Intervention Model Key Results
Muscle-invasive bladder cancer Cisplatin-ineligible patients with cT2-4aN0-1M0 muscle-invasive bladder cancer (NCT04610671) Intravesical cretostimogene grenadenorepvec (oncolytic serotype 5 adenovirus encoding granulocyte-macrophage colony-stimulating factor) with systemic nivolumab No dose-limiting toxicity was encountered in 21 patients enrolled and treated; pathologic complete response rate of 42.1% and 1-year recurrence-free survival rate of 70.4%

The Evolving NMIBC Treatment Landscape and Cretostimogene's Place

Non-muscle-invasive bladder cancer (NMIBC) comprises approximately 75% of new bladder cancer cases, with upfront treatment for high-risk disease typically Bacillus Calmette-Guérin (BCG) after transurethral tumor resection. Patients with BCG-unresponsive, intolerant, or refractory disease face high risk of recurrence and progression to muscle invasive disease, with early radical cystectomy being the standard approach for this setting. Over the past decade, investigational trials have expanded bladder-sparing options for BCG-unresponsive NMIBC with carcinoma in situ (CIS), leading to FDA approval of intravesical nadofaragene firadenovec, nogapendekin alfa inbakicept, and systemic pembrolizumab. On December 16, 2022, the FDA approved the adenoviral vector-based gene therapy nadofaragene firadenovec-vncg (brand name Adstiladrin) for adult patients with high-risk BCG-unresponsive NMIBC with CIS, based on Study rAd-IFN-CS-003 in 98 evaluable patients who received intravesical instillations (75 mL of nadofaragene firadenovec at 3 × 1011 viral particles per mL) once every 3 months, where fifty subjects experienced CR 3 months after the initial treatment (CR = 51%; 95% confidence interval, 40.7; 61.3%), of whom 46% remained in response for ≥12 months, with median duration of response of 9.7 months (range: 3-52+). TAR-200, a novel intravesical drug-releasing system, received United States Food and Drug Administration approval on 09/09/2025 for BCG-unresponsive high-risk NMIBC with CIS.

Published phase 2 trial data define durable complete response (CR) and bladder preservation with novel intravesical and combination regimens. In QUILT-3.032, participants received 400 mcg nogapendekin alfa inbakicept (NAI) in combination with 50 mg BCG through intravesical instillation weekly for 6 weeks, with optional reinduction if complete response (CR) was not achieved at month 3, with CR rate (n = 100) of 71% (95% CI, 61.1-79.6) with a median DOR of 26.6 months (range, 0.03-53.62), cystectomy-free rate in the 71 responders at 24 and 36 months of 90.3% (95% CI 79.7-95.6) and 84.2% (95% CI 69.6-92.1), respectively, and disease-specific survival (DSS) of 100% (95% CI 100.0-100.0) at 12 months and 98.2% (95% CI 88.2-99.8) at 36 months. In the phase 2 CORE-001 trial (NCT04387461), 35 patients with BCG-unresponsive NMIBC with CIS were treated with intravesical cretostimogene with systemic pembrolizumab, with induction cretostimogene administered weekly for 6 weeks followed by three weekly maintenance infusions at months 3, 6, 9, 12 and 18 in patients maintaining CR and pembrolizumab administered for up to 24 months, with CR rate in the intention-to-treat population at 12 months of 57.1% (20 out of 35, 95% confidence interval (CI) 40.7-73.5%), 29 out of 35 patients (82.9%, 95% CI 70.4-95.3%) deriving CR at 3 months, median follow-up of 26.5 months with median duration of response not reached (95% CI 15.7 to not reached), CR rate at 24 months of 51.4% (18 out of 35) (95% CI 34.9-68.0%), and no patient progressing to muscle-invasive bladder cancer. In a prospective single-arm open-label phase 2 trial of combination intravesical gemcitabine and docetaxel (GemDoce) given weekly for 6 weeks as induction followed by monthly maintenance for 2 years in 25 patients with BCG-naïve high-risk NMIBC, the 3-month complete response rate was 100% and recurrence-free survival at 12 months was 92%, with updated high-grade recurrence-free survival of 84% at 24 months (21/25; 95% CI, 63%-94%) and 80% at 36 months (20/25; 95% CI, 58%-91%). In SWOG S1605, intravenous atezolizumab every 3 wk for 1 yr in BCG-unresponsive high-risk NMIBC produced CR at 6 mo in 20 of 74 patients with CIS (27%), median duration of response of 17 mo with 56% (95% confidence interval [CI] 34-77%) durable to at least 12 mo, and 18-mo actuarial event-free survival rate among 55 patients with Ta/T1 disease of 49% (90% CI 38-60%).

Safety and practice data differentiate intravesical from systemic intensification. A systematic review and meta-analysis of three phase III trials including 1895 patients comparing BCG plus anti-programmed cell death protein 1/programmed death-ligand 1 immune checkpoint inhibitors with BCG alone in BCG-naïve high-risk NMIBC showed increased risk of any-grade treatment-related adverse events [RR 1.25, 95% confidence interval (CI) 1.20-1.31, P < 0.00001], grade ≥3 TRAEs (RR 4.02, 95% CI 3.06-5.30, P < 0.00001), serious adverse events (RR 4.54, 95% CI 2.09-9.85, P = 0.0001), any-grade immune-related adverse events (RR 15.18, 95% CI 4.34-53.14, P < 0.0001), grade ≥3 irAEs (RR 9.99, 95% CI 2.12-47.14, P = 0.004), and treatment discontinuation (RR 2.87, 95% CI 1.50-5.52, P = 0.002), with toxicity mainly driven by systemic immune-mediated events whereas local BCG-related urinary adverse events were largely comparable. By contrast, adverse events attributed to cretostimogene were low grade, self-limiting and predominantly limited to bladder-related symptoms, with 5 out of 35 patients (14.3%) developing grade 3 treatment-related adverse effects and no evidence of overlapping or synergistic toxicities, and treatment-related adverse events with NAI plus BCG were largely grade 1 to 2 (61%), with 3% grade 3 and no grade 4 or 5 treatment-related adverse event. Grade 3-5 treatment-related adverse events occurred in 26 patients (16%) in SWOG S1605, including three treatment-related deaths, and 12 of 129 eligible patients experienced progression to muscle-invasive or metastatic disease. Global BCG shortages and the substantial impact of cystectomy on quality of life underscore continued reliance on intravesical chemotherapy, with approximately 70% of US physicians identifying either gemcitabine (∼40%) or mitomycin C (∼30%) as the most often used intravesical chemotherapies for BCG-unresponsive and BCG-exposed groups, while radical cystectomy was recommended by 50% of Arab urologists for BCG-unresponsive disease followed by intravesical chemotherapy (30%), repeat BCG therapy (12%), and resection with ongoing surveillance (8%).

Frequently Asked Questions

What is the mechanism of action of cretostimogene grenadenorepvec in non-muscle invasive bladder cancer?
Cretostimogene grenadenorepvec is an oncolytic immunotherapy designed to selectively replicate within and lyse cancer cells. This replication process also stimulates an anti-tumor immune response within the bladder microenvironment. Its intravesical administration allows for direct targeting of bladder cancer cells while potentially minimizing systemic toxicity.
How does cretostimogene grenadenorepvec address unmet needs in the treatment of non-muscle invasive bladder cancer?
Many patients with high-risk NMIBC face recurrence or progression despite standard Bacillus Calmette-Guérin (BCG) therapy, often leading to radical cystectomy. Cretostimogene grenadenorepvec offers a novel, bladder-sparing therapeutic option for these challenging cases, particularly in BCG-unresponsive settings. It aims to provide an effective alternative for patients who have limited treatment options.
Which patient populations with non-muscle invasive bladder cancer are candidates for cretostimogene grenadenorepvec?
Cretostimogene grenadenorepvec is primarily being evaluated for patients with high-risk non-muscle invasive bladder cancer, especially those who are unresponsive to or intolerant of BCG therapy. This includes individuals with carcinoma in situ (CIS) with or without concomitant papillary tumors. The drug's role is to provide an alternative to radical cystectomy in this challenging population.
What are the key considerations for the safety profile of cretostimogene grenadenorepvec in NMIBC?
As an intravesical oncolytic immunotherapy, the safety profile of cretostimogene grenadenorepvec typically involves local bladder-related adverse events. These can include dysuria, hematuria, and bladder spasm, which are generally manageable. Systemic adverse events are less common due to its localized administration, but clinicians monitor for any signs of immune-related reactions or infections.

References

  1. [1] Gabriel PE, Roumiguié M et al.. The Evolving Landscape of Systemic Immunotherapy for Bacillus Calmette-Guérin-naïve High-risk Non-muscle-invasive Bladder Cancer: At the Edge of a Tsunami?. European urology oncology. 2025 Aug. 40752989
  2. [2] Filon M, Schmidt B. New Treatment Options for Non-Muscle-Invasive Bladder Cancer. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2025 Jan. 39933135
  3. [3] Necchi A, Raggi D et al.. Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. European urology. 2020 Apr. 31708296
  4. [4] Fazaa N, Shashar R et al.. [INNOVATIONS IN THERAPIES FOR BACILLUS CALMETTE-GUERIN (BCG) FAILURE NON-MUSCLE INVASIVE PATIENTS]. Harefuah. 2025 Sep. 40932192
  5. [5] Meghani K, Cooley LF et al.. First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Guérin. European urology. 2022 Dec. 36008193
  6. [6] Peyton CC, Chipollini J et al.. Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: how, when and what. World journal of urology. 2019 Oct. 30535583
  7. [7] Achard V, Fournier B et al.. Radiotherapy Combined with a Radiosensitizer for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Carcinoma In Situ Bladder Cancer: An Open-label, Single-arm, Multicenter, Phase 2 European Organisation for Research and Treatment of Cancer Trial. European urology oncology. 2024 Oct. 38556413
  8. [8] Huang X, Wang X et al.. Mechanisms, Clinical Trials, and New Treatments for BCG-Unresponsive in Nonmuscle Invasive Bladder Cancer. Cancer medicine. 2025 Sep. 40948378
  9. [9] Zeng J, Funk J et al.. Gemcitabine as first-line therapy for high-grade non-muscle invasive bladder cancer: results from a tertiary center in the contemporary BCG-shortage era. Translational andrology and urology. 2023 Jun 30. 37426602
  10. [10] Deininger S, Törzsök P et al.. From Interferon to Checkpoint Inhibition Therapy-A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette-Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC). Cancers. 2022 Jan 29. 35158964
  11. [11] Albakr A, Narayan VM et al.. Pharmacotherapy for bladder spasm and irritative lower urinary tract symptoms associated with intravesical therapy for bladder cancer: a review of available evidence. Translational andrology and urology. 2025 Oct 31. 41230142
  12. [12] Grandi P, Darilek A et al.. Intravesical Infusion of Oncolytic Virus CG0070 in the Treatment of Bladder Cancer. Methods in molecular biology (Clifton, N.J.). 2023. 37410243
  13. [13] Colbert L, Jia Y et al.. FDA Approval Summary: Nadofaragene Firadenovec-vncg for Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025 Apr 1. 39705065
  14. [14] Moyer JA, Mi L et al.. Real-world outcomes of nadofaragene firadenovec for BCG-unresponsive non-muscle-invasive bladder cancer: A multicenter experience. Urologic oncology. 2026 Feb. 41253655
  15. [15] Abou Chakra M, Duquesne I et al.. Decoding Immune Mechanisms in BCG-unresponsive Non-muscle Invasive Bladder Cancer. Frontiers in bioscience (Landmark edition). 2026 Apr 30. 42216552
  16. [16] Chevuru PT, McElree IM et al.. Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer. Urologic oncology. 2023 Mar. 36456454
  17. [17] Ciccarese C, Occhipinti D et al.. Safety profile of BCG with or without immunotherapy in non-muscle-invasive bladder cancer (NMIBC): a systematic review and meta-analysis. ESMO open. 2026 Oct. 42777327
  18. [18] Li R, Shah PH et al.. Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial. Nature medicine. 2024 Aug. 38844794
  19. [19] Steinmetz AR, Jazayeri B et al.. Integrating gene therapy into the treatment paradigm for non-muscle invasive bladder cancer. Expert opinion on biological therapy. 2025 Jan-Feb. 39779686

Contact Us

📍

Address

350 Springfield Avenue,
Suite #200 Summit, NJ 07901

✉️

For General Inquiry

info@pienomial.com

Related Posts